Qiming Venture Partners' 16th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
China's high-quality companies have reached a valuation level that's become genuinely attractive.
Recently, Qiming Venture Partners held its 16th RMB Fund Annual Meeting and Investor Summit in Shanghai.
(Roundtable and panel discussion guests are listed in alphabetical order by surname)
Duane Kuang, Founding Managing Partner of Qiming Venture Partners, delivered the opening address, sharing the firm's progress over the past year as well as its market insights and assessments. He noted that Qiming Venture Partners is itself an enterprise that must continually renew and iterate itself, maintaining a sense of vigilance even in times of stability. He believes that Chinese assets have been undervalued in recent years, and that after a period of adjustment, the potential of quality Chinese enterprises has reached a highly attractive valuation level.
Jun Qian, Executive Dean of Fudan University's International School of Finance and Professor of Finance, delivered a keynote speech titled "China's Macroeconomic Analysis and Forecast," analyzing the current state of China's macroeconomic development and the challenges it faces, as well as how new incremental policies can help drive a comprehensive economic recovery.
In the roundtable discussion "LPs and GPs Co-Creating a New Ecosystem," Kuang served as moderator, joined by Wang Wenhuai, Chairman of C&D Emerging Investment, Zhi Wen, General Manager of Shanghai SDIC Pioneer Fund Management, and Xu Qing, Managing Partner of OrizaFoFs. They shared perspectives on the ideal state of RMB funds under current market conditions, key metrics to prioritize, and their observations and assessments of new initiatives by GPs.
In the second roundtable discussion, William Hu, Managing Partner of Qiming Venture Partners, served as moderator, joined by He Miao, Deputy General Manager of Shanghai SDIC Pioneer Fund Management, Li Huaijie, Senior Partner of OrizaFoFs, and Yuan Zhide, Executive Vice President of Shanghai Science and Technology Innovation Fund. They discussed "China's Innovation Capacity and Investment Opportunities from an LP Perspective," sharing their judgments on the global innovation value of the healthcare industry and investment timing.
The humanoid robotics industry is currently undergoing a critical leap from technology validation to commercialization. As a leader in humanoid robots and a pioneer in intelligent service robotics, UBTECH (09880.HK) is one of the very few companies globally with full-stack humanoid robotics capabilities, and has been among the first to achieve real-world deployment of humanoid robots. In the dialogue "Envisioning the Future of Humanoid Robotics," Kuang and Zhou Jian, Founder, Chairman and CEO of UBTECH, discussed the industry's current landscape and positioning, economics and efficiency, as well as UBTECH's competitive advantages and development strategy.
Standing at the threshold of the AI 2.0 era, a new wave of AI plus hardware is beginning. With groundbreaking panoramic imaging technology, Insta360 has rapidly become one of the world's most popular smart imaging brands in less than a decade — a success built on precise grasp of technology and market trends. In the dialogue "Pioneering Original Innovation in 'AI + Hardware'," Alex Yeh, Partner at Qiming Venture Partners, and JK, Founder and Chairman of Insta360, shared insights on the sources of Insta360's innovative DNA, product strategy and breakthroughs, directions for AI technology application, and global development strategy.
In the medical field, AI applications are gradually moving from theory to practice. Surgical robots represent the culmination of frontier technologies. As a leader in this space, how does Cornerstone Robotics view the application prospects of next-generation AI technology in surgical robotics? In the dialogue "Building Surgical Robots at the 'Tip of the Pyramid'," Hu and Guowei Ou, Professor at The Chinese University of Hong Kong and Founder and CEO of Cornerstone Robotics, discussed Ou's entrepreneurial journey and reflections, Cornerstone's technical breakthroughs and advantages, AI technology innovation, as well as corporate culture and business philosophy.
As AI technology moves from exploration to the deep waters of industry, Chinese enterprises' technical strength and development potential are increasingly evident. StepFun is an industry-leading general-purpose large model startup actively exploring practical pathways for large models across multiple domains. Where will AI technology head, and how will it profoundly reshape industries? In the dialogue "StepFun: Exploring the 'Uncharted Territory' of AI Entrepreneurship," Alex Zhou, Managing Partner at Qiming Venture Partners, served as moderator, joined by Daxin Jiang, Founder and CEO of StepFun. They discussed the development path toward AGI, StepFun's differentiated advantages in the market, and the deployment of AI Agents at the application level.
Chinese innovative drug exports have reached record highs — where is innovative drug investment heading? In the panel discussion "Innovative Drug Globalization," Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare, served as moderator, joined by Qin Ying, Founder, Chairman and CEO of LaNova Medicines, and Xue Tongtong, Founder, Chairman and CEO of MediLink Therapeutics. They discussed the evolution of China's innovative drug industry, the core drivers behind globalization, and the construction of overseas expansion capabilities.
In the panel discussion "Global Innovation in Medical Devices, Made in China," Zhang Ao, Partner at Qiming Venture Partners, served as moderator, joined by Cynthia Chen, Chairman and Executive President of Pulnovo Medical, and Hu Jifan, Chairman and General Manager of Shenzhen Hongji Medical. They shared their companies' market positioning and technical breakthroughs, international competition strategies, and how to anchor innovation with a global perspective while reshaping the future of healthcare with Chinese ingenuity.
Currently, Chinese technology brands are writing entirely new business narratives in the global market. Brand globalization is no longer simply about expanding into individual markets, but about the global reconstruction of technological paradigms and business ecosystems. As China's first electric heavy-duty truck startup to achieve mass production and delivery, DeepWay is actively exploring global markets. In the dialogue "A New Paradigm for Chinese Technology Brands Going Global," Zhou and Wan Jun, Chairman and CEO of DeepWay, discussed DeepWay's development speed and core strategy, as well as reflections on globalization and overseas expansion strategy.
The generative AI industry is transitioning from super models to super applications, with 2025 seen as the year of comprehensive AI application deployment. Globally, China has become an important market for AI application and development, with several leading enterprises having accumulated substantial experience. In the panel discussion "Consensus and Non-Consensus: The Decisive Moment for AI Deployment," Zhou joined Luo Yihang, CEO of Shengshu Technology, and Huaiting Zhang, CEO of Yuaiweiwu, to discuss AI technology maturity and deployment challenges, key strategies for commercialization and user trust, organization and talent management, as well as analysis of industry competition and future outlook.
Past Highlights
Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including Top 5 Best VC Firms in China at ChinaVenture's 2024 Rankings Qiming Honors | Qiming Venture Partners Ranks 5th in Zero2IPO's 2024 China VC Rankings Among Five Major Awards Qiming Perspectives | Duane Kuang: The Time Is Right for Chinese Technology to Go Global
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting through listings on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.